Multi-center randomized open label phase II trial on three rituximab dosing schemes in immune thrombocytopenia patients

  • JJ Zwaginga
  • , Ronnie van der Holt
  • , Peter te Boekhorst
  • , BJ Biemond
  • , MD Levin
  • , R van der Griend
  • , A Brand
  • , S Zweegman
  • , HFM Pruijt
  • , Viera M.J. Novotny
  • , A Vreugdenhil
  • , MR De Groot
  • , O de Weerdt
  • , E C M van Pampus
  • , T M van Maanen-Lamme
  • , S Wittebol
  • , MR (Martin) Schipperus
  • , MH Silbermann
  • , PC Huijgens
  • , Marleen Luten
  • Rene Hollestein, J A C Brakenhoff, JG Schrama, FAA Valster, G A Velders, H R Koene, Hovon Study Grp Dutch

Research output: Contribution to journalArticleAcademicpeer-review

21 Citations (Scopus)
Original languageUndefined/Unknown
Pages (from-to)E90-E92
JournalHaematologica
Volume100
Issue number3
DOIs
Publication statusPublished - 2015

Research programs

  • EMC MM-02-41-03

Cite this